FSFatma I. Sonbol

Fatma I. Sonbol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatma I. Sonbol has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing the power of ferulic acid as a dual-action strategy against biofilm-forming extensively drug-resistant Acinetobacter baumannii isolated from cancer patients: in vitro and in vivo study

    by Noha A. Attia, Fatma I. Sonbol, Amal M. Abo-Kamar, Lamiaa A. Al-Madboly, Ahmed A. Abdelaziz

    The increasing prevalence of extensively drug-resistant Acinetobacter baumannii (XDRAb), particularly biofilm-producing strains, poses a significant threat to clinical management, especially in immunocompromised patients. This study investigates the potential of ferulic acid (FA) as a dual-function therapeutic agent with antibacterial and antibiofilm capabilities. A total of 34 XDRAb isolates were obtained from cancer patients, and FA’s activity was assessed using a range of in vitro assays and in vivo neutropenic rat wound infection model. FA exhibited marked antimicrobial activity against XDRAb (MIC: 512 to 1024 µg/mL). At su-binhibitory concentrations (¼ and ½ MIC), FA significantly inhibited biofilm formation by 43.2 and 67.6% and disrupted established biofilms by 29.4 and 54.8% ( p < 0.05), respectively. Consistent with these effects, FA also reduced cell surface hydrophobicity and exopolysaccharide production in XDRAb isolates. Microscopic imaging via light, scanning electron, and confocal laser scanning microscopy corroborated these findings, revealing substantial structural degradation of biofilms upon treatment. At the molecular level, FA significantly downregulated ( p < 0.05) the key biofilm-associated genes ( abaI , bfmR , bap , csuE , and pgaB ), as quantified by RT-qPCR. In vivo, FA significantly enhanced the wound healing rates (approximately 82%, p < 0.05) and reduced the wound bacterial burden ( p < 0.05). Histopathological examination showed near-complete restoration of epithelium architecture seven days post-treatment in the FA-treated group. Collectively, this study demonstrates that FA exerts combined antimicrobial and antibiofilm activities against XDRAb in preclinical models. Our findings indicate that FA interferes with multiple stages of biofilm development while exhibiting antibacterial activity at higher concentrations. These results support further investigation of FA as antibiofilm or adjunct candidate, particularly for localized biofilm-associated XDRAb infections.

  • Open Access

    Unlocking p-coumaric acid’s potential against biofilm-forming extensively drug-resistant Acinetobacter baumannii: in vitro and in vivo study

    by Noha A. Attia, Ahmed A. Abdelaziz, Fatma I. Sonbol, Amal M. Abo-Kamar, Lamiaa A. Al-Madboly

    Background: The global rise of extensively drug-resistant Acinetobacter baumannii , particularly biofilm-forming strains, has drastically limited treatment options and created an urgent need for novel therapies to restore antibiotic efficacy. This study explored p-coumaric acid ( p -CA) as a potential dual-action agent to combat biofilm-associated XDR Acinetobacter baumannii infections and restore imipenem efficacy. Methods: Among 100 clinical Acinetobacter baumannii isolates, 32 were identified as XDR and exhibited resistance to imipenem. The antimicrobial and antibiofilm efficacy of p -CA was systematically evaluated through comprehensive in vitro assays and an in vivo rat infection model. Minimum inhibitory concentrations were determined via the broth microdilution method, and the potential modulation effect on imipenem efficacy was investigated. To assess biofilm inhibition and disruption, quantitative analyses were performed using the crystal violet staining technique, complemented by evaluating its impact on the bacterial cell surface hydrophobicity and exopolysaccharide production. Biofilm structural changes were analyzed via light, scanning electron, and confocal laser scanning microscopy. Additionally, the expression levels of key biofilm-associated genes were quantified via quantitative reverse transcription PCR. Results: The p -CA exhibited potent antimicrobial activity against the tested isolates (MIC: 512 µg/mL) and synergized with imipenem, reducing its MIC by 512-fold. At subinhibitory concentrations (¼–½ MIC), it inhibited biofilm formation (66.2–80.5%, p < 0.05) and disrupted pre-formed biofilms (45.8–71.3%, p < 0.05), likely via altered cell surface hydrophobicity and reduced EPS production. Microscopic imaging corroborated these findings, revealing substantial structural degradation of biofilms upon treatment. At the molecular level, p -CA significantly downregulated ( p < 0.05) the key biofilm-associated genes ( abaI , bfmR , bap , csuE , and pgaB ), as quantified by RT-qPCR. In vivo, the p -CA/imipenem combination significantly enhanced the survival rates (100%, p < 0.05) and reduced the lung bacterial burden ( p < 0.001). Histopathological examination showed near-complete restoration of alveolar architecture by 72 h post-treatment in the combination therapy group. Conclusion: These findings position p -CA as a promising dual-action adjuvant against XDR Acinetobacer baumannii infections, particularly in biofilm-associated contexts. It combines direct antimicrobial activity, biofilm disruption, and synergy with imipenem to address critical treatment gaps.


  • Open Access

    Fosfomycin at sub-minimum inhibitory concentration impairs biofilm and efflux pump activity in multidrug-resistant Klebsiella pneumoniae isolates

    by Marwa W. Moustafa, Tarek E. El-Banna, Fatma I. Sonbol, Maisra M. El-Bouseary

    Background: Klebsiella pneumoniae plays a critical role in hospital-acquired infections, which pose a serious threat globally. Older antibiotics such as fosfomycin are being reconsidered to combat MDR K. pneumoniae . In healthcare settings, bacteria are exposed frequently to antibiotics at sub-inhibitory concentrations (sub-MICs), which may alter their virulent characteristics. The aim of this research was to investigate the impact of fosfomycin at sub-MICs on the virulence determinants of MDR K. pneumoniae . Methods: The effect of sub-MIC fosfomycin treatment on biofilm formation was evaluated by crystal violet assay and confocal laser scanning microscopy (CLSM). The cartwheel technique was employed to study efflux pump activity phenotypically. The expression of genes of biofilm ( fimH , mrkD ) and efflux pump ( acrA , acrB ) was determined using reverse transcription quantitative PCR (RT-qPCR). Scanning electron microscopy (SEM) was also utilized to visualize the morphological changes. Results: The MIC of fosfomycin against K. pneumoniae MDR isolates ranged from 256 to 1024 µg/mL. The biofilm formation ability of isolates ( n = 50) was reduced significantly ( P < 0.05) following the exposure to ¼ MIC of fosfomycin. CLSM analysis revealed disruption of biofilm structure, reduced thickness and density, and increased percentages of dead cells. RT-qPCR revealed 20–60% downregulation of fimH and mrkD and downexpression of acrA and acrB . SEM analysis showed pronounced morphological changes, including a characteristic cauliflower-like deformation. Conclusion: Fosfomycin at sub-inhibitory levels is able to disrupt biofilm architecture and the efflux pump activity in MDR K. pneumoniae , pointing to its possible role as an adjunct agent in combating antibiotic resistance.

  • Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties

    by Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Maisra M. El-Bouseary, Fatma I. Sonbol, Gaber El-Saber Batiha

    Hyperviscosity syndrome (HVS) recently emerged as a complication of coronavirus disease 2019 (COVID-19) and COVID-19 vaccines. Therefore, the objectives of this critical review are to establish the association between COVID-19 and COVID-19 vaccines with the development of HVS. HVS may develop in various viral infections due to impairment of humoral and cellular immunity with elevation of immunoglobulins. COVID-19 can increase blood viscosity (BV) through modulation of fibrinogen, albumin, lipoproteins, and red blood cell (RBC) indices. HVS can cause cardiovascular and neurological complications in COVID-19 like myocardial infarction (MI) and stroke. HVS with or without abnormal RBCs function in COVID-19 participates in the reduction of tissue oxygenation with the development of cardio-metabolic complications and long COVID-19. Besides, HVS may develop in vaccine recipients with previous COVID-19 due to higher underlying Ig concentrations and rarely without previous COVID-19. Similarly, patients with metabolic syndrome are at the highest risk for propagation of HVS after COVID-19 vaccination. In conclusion, COVID-19 and related vaccines are linked with the development of HVS, mainly in patients with previous COVID-19 and underlying metabolic derangements. The possible mechanism of HVS in COVID-19 and related vaccines is increasing levels of fibrinogen and immunoglobulins. However, dehydration, oxidative stress, and inflammatory reactions are regarded as additional contributing factors in the pathogenesis of HVS in COVID-19. However, this critical review cannot determine the final causal relationship between COVID-19 and related vaccines and the development of HVS. Prospective and retrospective studies are warranted in this field.